In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Consumer Healthcare Co. Ltd.

Division of Takeda Pharmaceutical Co. Ltd.
www.takeda.com

Latest From Takeda Consumer Healthcare Co. Ltd.

Biopharma Quarterly Deal-Making Statistics, Q1 2017

Biopharma financing decreased by 29% in the first quarter of 2017; conversely, M&As set a record, reaching $61.9 billion. The largest alliance of the quarter involved the microbiome.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, March 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.

Deals BioPharmaceutical

P&G Targets Proposed Nexium Switch In Petition For PPI Labeling Limits

A P&G petition revives the firm’s argument that future OTC proton pump inhibitors should be held to the same labeling language as Prilosec OTC. The firm also argues that the NDA process can allow labeling that unfairly gives some products marketplace advantages over category competitors.

Consumer BioPharmaceutical

P&G Targets Proposed Nexium Switch In Petition For PPI Labeling Limits

A P&G petition revives the firm’s argument that future OTC proton pump inhibitors should be held to the same labeling language as Prilosec OTC. The firm also argues that the NDA process can allow labeling that unfairly gives some products marketplace advantages over category competitors.

Consumer BioPharmaceutical
See All

Company Information

  • Industry
  • Pharmaceuticals
    • OTC, Consumer
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Masashi Sugimoto, Pres.
  • Contact Info
  • Takeda Consumer Healthcare Co. Ltd.
    Phone: (81)
    8-2, Marunouchi 1-chome
    Chiyoda-ku
    Tokyo, 100-0005
    Japan
Advertisement
Advertisement
UsernamePublicRestriction

Register